Itziar Arrieta‐Aldea

ORCID: 0000-0002-4655-4151
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV-related health complications and treatments
  • Bone and Joint Diseases
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • HIV Research and Treatment
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • HIV/AIDS Research and Interventions
  • Respiratory Support and Mechanisms
  • MicroRNA in disease regulation
  • Poxvirus research and outbreaks
  • HIV/AIDS oral health manifestations
  • Lymphoma Diagnosis and Treatment
  • Influenza Virus Research Studies
  • COVID-19 and Mental Health
  • Immunotherapy and Immune Responses
  • Systemic Lupus Erythematosus Research
  • Herpesvirus Infections and Treatments
  • Dermatological and COVID-19 studies

Hospital Del Mar
2020-2025

Universitat Autònoma de Barcelona
2024

Hospital del Mar Research Institute
2022

Universitat Pompeu Fabra
2022

Jesús Rodríguez‐Baño Jerónimo Pachón Jordi Carratalà Pablo Ryan Inmaculada Jarrín and 95 more María Yllescas José Ramón Arribas Juan Berenguer Esther Aznar Muñoz Pedro Gil Divasson Patricia González Muñiz Clara Aguirre Marta Díaz‐Menéndez Fernando Calle Marta Arsuaga Vicente Elena Trigo Esteban Ignacio Valero Rosa de Miguel Buckley Julen Cadiñanos Beatriz Díaz‐Pollán Luz Martín‐Carbonero Juan Carlos Ramos Ramos Belén Loeches Yagüe Rocío Montejano Juan González‐García Julio García‐Rodríguez Juan Berenguer Margarita Ramírez Isabel Gutiérrez Francisco Tejerina Teresa Aldámiz‐Echevarría Cristina Díez Chiara Fanciulli Leire Pérez‐Latorre Blanca Pinilla Juan Carlos López Ana Such Díaz Elena Álvaro Alonso Juan Torres Macho Guillermo Cuevas Eva Jiménez Fátima Brañas Baztán Jorge Valencia de la Rosa Mario Pérez Inés Fernández Jiménez Gemma Muñiz Nicolás Antonia Sepúlveda Berrocal Alberto Gato Díez María Pilar Toledano Sierra María Paz García Butenegro Ana Isabel Peláez Ballesta Elena Morcillo Rodríguez Isidoro Fernández Romero Cristina Peláez Ballesta María Isabel Guirado Torrecillas Josune Goikoetxea Elena Bereciartua Bastarrica Laura Guío Carrión Regino Rodríguez Marta Ibarrola Hierro Isabel Hernández Inés Pérez Zapata Sergio Román Soto Mohamed Kallouchi Juan Ramón Domínguez Vicent Rafae Silvariño Fernández Jon Ugalde Espiñeira Ainhoa Sanjuan López Silvia García Martínez Mikel Temprano Gogenola Víctor Asensi Silvia Suárez Lucia Suárez Carmen Yllera María Rivas-Carmenado Alberto Romero-Palacios Jesús Ruiz Aragón Patricia Jiménez Aguilar Ma Luisa Fernández Ávila Rosario Castilla Ortiz Vanesa Alende Castro Cristina Pérez García Marta Fernández Morales María Lorena María Valle Feijoo Begoña Rodríguez Ferreira Joan Gómez‐Junyent Judit Villar-García Inmaculada López-Montesinos Itziar Arrieta‐Aldea Abora Rial‐Villavecchia Elisa García Vázquez Aychel Elena Roura Piloto Encarnación Moral Escudero Alicia Hernández Torres Helena Iglesias David Vinuesa García Clara Martínez Montes Francisco Javier de la Hera Fernández Francisco Anguita-Santos Andrés Ruiz Sancho Vicens Díaz-Brito

ObjectivesThe objective of this study was to estimate the association between tocilizumab or corticosteroids and risk intubation death in patients with coronavirus disease 19 (COVID-19) a hyperinflammatory state according clinical laboratory parameters.MethodsA cohort performed 60 Spanish hospitals including 778 COVID-19 data indicative state. Treatment mainly tocilizumab, an intermediate-high dose (IHDC), pulse (PDC), combination therapy, no treatment. Primary outcome death; follow-up 21...

10.1016/j.cmi.2020.08.010 article EN cc-by-nc-nd Clinical Microbiology and Infection 2020-08-27

ABSTRACT Background Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19 which evidence from controlled clinical trials lacking. Methods We conducted multi-center, randomized trial in patients hospitalized COVID-19. All received standard of care treatment, including off-label use marketed medicines, and were 1:1 to receive one dose (250-300 mL) CP donors IgG anti-SARS-CoV-2. The primary endpoint was the proportion categories 5, 6 or 7 ordinal scale at day...

10.1101/2020.08.26.20182444 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2020-09-01

Background The impact of tenofovir disoproxil fumarate (TDF) antiretroviral (ART) regimens on bone health has been characterized mostly by mineral density (BMD), but recently also quality (BQ). aim this pilot study is to assess the changes in BMD and BQ after switch from TDF alafenamide (TAF) ART. Methods HIV individuals receiving TDF-based ART were randomized Bictegravir-TAF-Emtricitabine or remain same regimen. At baseline 24-weeks randomization, participants underwent (BMD) DXA assessment...

10.3389/fendo.2023.1076739 article EN cc-by Frontiers in Endocrinology 2023-03-27

This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH).The retrospective conducted from April 2019 to November 2022, included PLWH < 50 copies/mL HIV-RNA prior recruitment who initiated either D/L or B/F/T switching therapy. The primary objective was evaluate treatment discontinuation rates; virologic outcomes were also evaluated.690...

10.1080/25787489.2023.2239564 article EN cc-by-nc HIV Research & Clinical Practice 2023-07-26

Abstract People living with human immunodeficiency virus (HIV) are the individuals most affected by current Monkeypox outbreak that was first announced in May 2022. Here we report Pan‐pox‐specific T‐cell responses a cohort of HIV‐1‐infected after receiving nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination safe without major side effects. Dose‐sparing i.d. superior to s.c. promoted polyfunctionality, expression...

10.1002/jmv.29317 article EN cc-by Journal of Medical Virology 2023-12-27

Abstract Purpose To design a randomized clinical trial to assess the efficacy and safety of favipiravir in patients with COVID-19 disease pneumonia. Methods A randomized, double blind, placebo-controlled pneumonia was conducted three Spanish sites. Randomization 1:1 or placebo (in both groups added Standard Care) performed treat The primary endpoint “time improvement,” measured as an improvement for ≥ two categories on 7-point WHO ordinal scale up 28 days' time frame. Results Forty-four were...

10.1186/s41479-023-00124-6 article EN cc-by Pneumonia 2024-02-25

Abstract Introduction People with HIV (PWH) poor immune response despite adequate antiretroviral treatment (ART) are susceptible to non-AIDS-related health issues. This study seeks evaluate bone quality in immunological nonresponders (INRs) comparison those proper (IRs) using vivo microindentation quantify quality, addition conventional mineral density (BMD) evaluations. Methods A cross-sectional was conducted at Hospital del Mar Barcelona from January 2019 June 2023. Participants were...

10.1210/clinem/dgae786 article EN publisher-specific-oa The Journal of Clinical Endocrinology & Metabolism 2024-11-11

To compare clinical characteristics, outcomes, and resource consumption of patients with coronavirus disease 2019 (COVID-19) seasonal influenza requiring supplemental oxygen.Retrospective cohort study conducted at a tertiary-care hospital. Patients admitted because between 2017 2019, or COVID-19 March May 2020 oxygen were compared. Primary outcome: 30-day mortality. Secondary outcomes: 90-day mortality hospitalization costs. Attempted sample size to detect an 11% difference in was 187 per...

10.1093/cid/ciac314 article EN Clinical Infectious Diseases 2022-04-19

Abstract Objective The HIV infection is a chronic disease that causes neurocognitive impairment (NI) and has been related with early development of frailty. We aimed to study the main risk factors for disorders frailty in older adults. Materials methods Cross-sectional 40 individuals than 65 years under antiretroviral therapy Hospital del Mar (Barcelona) recruited between November 2019 October 2020. Data obtained through clinical scores blood sample evaluate NI analyzed non-parametric tests...

10.1186/s40001-022-00639-6 article EN cc-by European journal of medical research 2022-02-02

Abstract Background Bone mineral density (BMD) decreases with ART initiation a tenofovir disoproxil fumarate-containing regimen, although bone tissue quality increases. The impact of dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC)-based on health parameters is not clear. Objectives To study the DTG/ABC/3TC-based therapy in ART-naive individuals HIV after 48 weeks treatment. Methods An observational, prospective and analytical treatment-naive patients undergoing regimen at week follow-up....

10.1093/jac/dkaa254 article EN Journal of Antimicrobial Chemotherapy 2020-07-20

Introduction. Long-term non-progressors (LTNPs) are HIV-infected individuals (HIV+) whose viral replication is controlled. However, these experience complications associated with HIV, among them, bone remodeling impairment. This study aims to perform a comprehensive health assessment and its association the inflammatory status of HIV+ LTNPs. A cross-sectional was conducted comparing strength components (bone mineral density tissue quality) between age-, sex-, comorbidities-matched groups...

10.3390/jcm11102927 article EN Journal of Clinical Medicine 2022-05-22

Background: HIV infection produces a chronic inflammation which leads to early aging of people linving with HIV. The causes this persistent remain be unveil. Changes in microRNAs (miRNAs) expression the context may contribute different inflammatory response. Even though antiretroviral treatments (ART) have significantly increased patient survival, an underlying persist leading HIV-related comorbidities.\Objectives: To study differential circulating miRNAs treatment-naïve individuals compared...

10.2139/ssrn.3854603 article EN SSRN Electronic Journal 2021-01-01
Coming Soon ...